Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04623086 · ClinicalTrials.gov registry record · Phase 4
Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose
A Phase 4 study of Type 1 Diabetes, sponsored by University of Washington.
- Completed
- Registry status
- Phase 4
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT04623086: Completed Phase 4 study of Type 1 Diabetes, sponsored by University of Washington.
NCT04623086 is a Phase 4 study of Type 1 Diabetes that has completed, run by University of Washington. The registered enrollment target is 59 participants, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04623086, a Phase 4 study of Type 1 Diabetes, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates direct switching vs use of a bridging dose from insulin glargine to insulin degludec in type 1 DM patients. Half of the participants will receive a bridging insulin glargine dose along with the 1st dose of degludec, while other half will receive a placebo and 1st dose of degludec.
Primary Outcome
Change in percent time spent in target glycemic range (TIR, glucose 70-180 mg/dL, both values included) in the 48 hours before and the 48 hours after the 1st dose of IDeg.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Insulin Glargine
- DRUG Insulin Degludec
Study Locations (1)
Washington
- University of Washington Medicine Diabetes Institute at South Lake Union - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2020-02-14 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 4 |
What the finished NCT04623086 record still lists
NCT04623086 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04623086 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT04623086 about?
NCT04623086 is a clinical study titled "Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose". This study evaluates direct switching vs use of a bridging dose from insulin glargine to insulin degludec in type 1 DM patients. Half of the participants will receive a bridging insulin glargine dose along with the 1st dose of degludec, while other half will receive a placebo and 1st dose of deglude...
What is the current status of trial NCT04623086?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 59 participants. The study started on 2020-02-14. Estimated completion is 2023-12-31.
What conditions does trial NCT04623086 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT04623086?
The interventions under investigation include: Placebo (DRUG), Insulin Glargine (DRUG), Insulin Degludec (DRUG).
Who is sponsoring clinical trial NCT04623086?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04623086 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04623086's enrollment target sits among peer trials
59 83rd of 198 higher than 115 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extended Bolus for Meals in a Closed-loop System
RECRUITING · Phase 4
-
Cholesterol Lowering and Residual Risk in Diabetes, Type 1
RECRUITING · Phase 4
-
Diabetes in African Youth
RECRUITING · Phase 4
-
Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes
COMPLETED · Phase 4
-
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
COMPLETED · Phase 4
-
Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI